Daily PubMed evidence board
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
This randomized phase 3b trial tested whether two meningococcal vaccines-one protecting against serogroup B (4CMenB) and one protecting against serogroups…
Signal score64Research triage score
CertaintyLow-to-moderateVerify in full text
PMID42262312Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This randomized phase 3b trial tested whether two meningococcal vaccines-one protecting against serogroup B (4CMenB) and one protecting against serogroups A, C, W, and Y (MenACWY-CRM)-can be given together to healthy adolescents aged 16-18 years. The study found that giving both vaccines at the same visit produced similar immune responses and had a similar safety and side-effect profile as giving each vaccine separately. Most reactions were mild or moderate and no unexpected side effects were reported. These results support the option of administering both vaccines at the same visit in adolescent immunization programs, pending full-text review and local policy considerations.
Why it matters
- Addresses whether the serogroup B vaccine 4CMenB and the quadrivalent conjugate MenACWY-CRM can be given at the same visit to adolescents-relevant to adolescent meningococcal immunization schedules and program efficiency.
- Findings on co-administration safety and immunogenicity could inform policy (e.g., US ACIP) about simplifying vaccine visits and improving uptake in the 16-18-year age group.
- If valid, comparable immune responses and tolerability with co-administration reduce logistical barriers and may increase coverage in populations at elevated risk for invasive meningococcal disease.
Primary outcomes
- Non-inferiority of hSBA geometric mean titers after concomitant administration versus 4CMenB alone and MenACWY-CRM alone
- Vaccine safety and reactogenicity
Effect summary
Abstract-reported result: In adolescents aged 16-18 years randomized to concomitant versus separate administration, co-administration of 4CMenB and MenACWY-CRM met co-primary non-inferiority criteria for hSBA geometric mean titer ratios (lower 95% CI > 0.5) and showed comparable percentages with 4-fold rises and titers above lower limits. Safety and reactogenicity profiles were similar between concomitant and separate administration groups, with most reactions mild or moderate and no unexpected adverse events reported in the abstract.
Benefit-cost lens
| Quick take | Trial-level finding supports comparable immunogenicity and tolerability for concomitant versus separate administration; economic or program benefit claims need local costing, baseline disease risk, and coverage assumptions. |
|---|---|
| BCR anchor | 2 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assessment based only on PubMed metadata and abstract; full-text review needed to extract absolute immunogenicity metrics, detailed safety/adverse event rates, subgroup data, and protocol details. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Some concerns |
| Notes | Randomized, observer-blind phase 3b trial (positive design). Assessment is limited to abstract-level data; full-text needed to review randomization method, allocation concealment, blinding of outcome assessment, handling of missing data, pre-specified non-inferiority margins, multiplicity, and detailed safety event reporting. |
Harms, equity, conflicts & implementation
| Implementation | Full-text review to confirm detailed immunogenicity/safety data; stakeholder review (immunization program managers, clinicians); cost and logistics assessment for same-visit delivery; training and information updates for providers and consent processes. |
|---|---|
| Equity impact | Unclear from abstract. Equity implications depend on differential access to adolescent vaccination services, baseline coverage gaps, and whether co-administration changes clinic visit barriers in underserved groups. |
| Harms | Abstract reports comparable safety and reactogenicity with mostly mild or moderate reactions and no unexpected side effects; full-text needed for exact adverse event rates, serious adverse events, and subgroup safety analyses. |
| Registration | NCT04318548 |
| Replication | Unknown from abstract-only triage; prior infant co-administration study cited but independent replication in adolescents not reported in abstract. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.